Lipocine Q3 Loss Narrows to $0.7M on $2.3M Revenue; $21.5M Cash Funds Runway to Nov 2027
LPCN is trading near its 52-week low of $1.36 (8.1% above the low) on light trading volume (0.1× avg).
Summary
Lipocine's Q3 net loss narrowed to $0.7M on $2.3M of revenue, most of it one-time license and collaboration fees. Cash and securities of $21.5M, plus post-quarter ATM proceeds, fund operations through at least November 5, 2027, but further capital will be needed after that.
Key Events · Earnings and Guidance · LPCN
-
Q3 Loss Narrows Sharply
Net loss was $666,192, or $0.08 per share, versus $3.19M, or $0.59, a year earlier, while revenue rose to $2.29M from $114,574.
-
Revenue Is Mostly One-Time
Q3 revenue included a $1.5M one-time collaboration fee and $600K of licensing revenue; recurring TLANDO royalties were only $190,072.
-
Cash Runway to November 2027
Cash, equivalents and marketable securities totaled $21.5M at September 30, 2026, up from $14.9M at December 31, 2025; management says this funds operations through at least November 5, 2027.
-
ATM Keeps Funding the Business
In the first nine months, 2,083,276 shares were sold at a $6.67 weighted average for $13.5M net; after quarter-end, another 2,827,977 shares raised $7.8M net, leaving $25.2M available as of November 4, 2026.
Analysis · LPCN · Life Sciences
The headline revenue jump to $2.3M from $115K a year ago is mostly one-time: a $1.5M collaboration fee plus $600K of licensing revenue, leaving only $190K of recurring TLANDO royalties. The balance sheet is the real story. Cash and securities stood at $21.5M at quarter-end, and roughly $7.8M net raised through the ATM after the quarter gives management a stated runway through at least November 5, 2027. That runway depends on continued ATM selling: 2.08M shares went out in the first nine months at a $6.67 weighted average, and another 2.83M shares were sold after quarter-end, so the share count keeps climbing while the stock trades near $1.47. Spending is driven by the BLOOM Phase 3 study of LPCN 1154, and the company says it will need new capital after November 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LPCN was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $1.36 to $12.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.